The Website is reserved exclusively for non-U.S. Learn more about how to invest in the private market or register today to get started. The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. If you're already an Endpoints subscriber, enter your email below for a Please note the magic link is We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing. BioSplice Therapeutics . Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. Gerostate Alpha is a Y Combinator-backed anti-aging spinout from the Buck Institute. Brian, are there any of these that you think investors should want to have on their radar? Alternative splicing regulates genome potential by differentially joining or skipping gene segments at alternative splice sites. Biosplice Therapeutics. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. Samumed adopted a fresh operating philosophy from the beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. In January, Ikena announced IK-930, a TEAD inhibitor targeting the Hippo signaling pathway, has entered IND-enabling studies. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 Unlock this article along with other benefits by subscribing to one of our paid plans. Alfredo Naj Domingos prostate cancer was spreading. Boulder, Colo.-based Edgewise Therapeutics will also begin selling its common stock this morning on the Nasdaq under the ticker symbol EWTX. The stock will begin trading at $16 per share and are expected to net the company about $176 million from the IPO. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Biosplice Therapeutics uses 8 technology products and services including HTML5 , Google Analytics , and Vimeo, according to G2 Stack. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. The name Biosplice echoes our science much more than Samumed does.. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022. Some like Sana Biotechnology (SANA -0.81%) are still in preclinical. Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. Michael White, Ph.D. joins Samumed as Chief Scientific Officer, Samumed Taps Pfizers Michael White as Its Chief Scientific Officer, Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors, Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimers Disease, Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis, Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis. Nominate them for Endpoints annual report, Keytruda hits one primary endpoint for use before and after surgery in lung cancer. Vividion Therapeutics has filed to go public. The stick will trade under the ticker symbol IKNA.. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. The Motley Fool has a disclosure policy. SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing . Now, the biotech is laying off a large swath of its staff as it undergoes a pipeline overhaul. Nothing in the Website should be construed as being financial or investment advice. Find More Contacts for Biosplice Therapeutics, Edit Lists Featuring This Company Section, After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program, Live Long(er) And Prosper: A Look At Top VC Investments In Radical Life Extension, Dave Johnson Joins Biosplice Therapeutics Board of Directors, Greater San Diego Area Companies With More Than 50 Employees, Life Science Companies With Fewer Than 100 Employees, United States Companies With Less Than $50M in Revenue (Top 10K). Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice Therapeutics; Organogenesis Holdings; Techfields Pharma; Centrexion Therapeutics; Regeneron; Xalud Therapeutics; Bone Therapeutics; Key Highlights. Corporate Contact: Erich Horsley Biosplice Therapeutics, Inc. Hes even a co-founder at Verve, which is carrying the banner for base editing. Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. We'll e-mail you a link to set a new password. 308 followers 310 connections. S AN DIEGO Biosplice, once the world's most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of one of its late-stage medicines, a. Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 million worth of confidenc Brian Orelli: IPOs lately have been really early-stage. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. In December, Edgewise raised $95 million in a Series C financing round. Novartis can't make enough of it, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Alex Denner secures victory in Amarin vote, ousting chair and adding supporters to board, Whos charting paths for LGBTQ+ leaders in biopharma? Biosplice Therapeutics, Inc. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Price as of February 28, 2023, 4:00 p.m. EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Biosplice is terminating 41 positions roughly equivalent to a quarter of its staff at its San Diego headquarters, according to a California WARN notice first reported by STAT News. Amicus Therapeutics began March with word that the FDA has scheduled a pre-approval inspection of its potential treatment for Pompe disease. In January, the company secured $120 million in a Series B financing round. Content on the Website is provided for informational purposes only. All rights reserved. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. In human DNA, approximately 20,000 genes code for hundreds of thousands of distinct proteins required for normal tissue development and function. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities. Vividion Therapeutics has filed to go public. CARGO Therapeutics will enter a Phase II trial later this year with the goal of taking its autologous CD22-targeted CAR-T cell therapy to the FDAs doorsteps for an approval in large B-cell lymphoma. The company's claim to fame is that it's amassed a huge library of compounds, and it has a screening technology to help it find the needles in the haystack. Novartis can't make enough of it, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Keytruda hits one primary endpoint for use before and after surgery in lung cancer, Amicus eyes Pompe approval; Atea ends Dengue work; 2seventy, Travere line up offerings. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month just as the federal government recently did for those insured by Medicare. The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. About. Other companies have tried this with limited success, but Candel's phase 2 data looks promising. You better start looking for another job, the scientist said. Stemming from foundational discoveries in Wnt pathway. Biosplice Therapeutics's latest funding round was a Series B for $120M on April 15, 2021. Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. Your use of the Website and your reliance on any information on the Website is solely at your own risk. Biosplice Therapeutics's valuation in August 2018 was $12,000M. Jan 3, 2023 06:30am. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Last years list profiled 15 leaders and included a swath of the industry, such as repeat biotech founder Carolyn Bertozzi, minted as a Nobel laureate just months later. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for . Active, Closed, Last funding round type (e.g. *** - To view the data, please log into your account or create a new one. Copyright 2023 Forge Global, Inc. All rights reserved. Learn more about Biosplice Therapeutics stock. Unlock this article along with other benefits by subscribing to one of our paid plans. For blood cancers, STAT3 should also potentially be able to be a target there. Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.It was founded in 2008 by Osman Kibar.. Samumed's products in development target novel components of the Wnt signaling pathway. Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. Stemming from foundational discoveries in Wnt pathway. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need., Joy Ghosh, PhD, of Eventide Asset Management, added, Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. Chief Financial Officer and Chief Business Officer of Biosplice Therapeutics, Inc. San Diego County, California, United States. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. Who are Silicon Therapeutics 's competitors? Already registered? His research on drug delivery, which led him to co-found Moderna in 2010, went on to prove critical in developing the companys Covid-19 vaccine. Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. The approval request includes both a BLA and NDA. https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html, https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. Published: Mar 26, 2021 We'll e-mail you a link to set a new password. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Prior to its IPO, Unity has raised a total of US$290.6 M from seven funding rounds. Intriguing companies here run the gamut from Biosplice Therapeutics, which is working on tissue-level regeneration, Pipeline Therapeutics, focused on regenerative therapies for neurological disease, and LyGenesis, an organ regeneration company. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M Pretzel Therapeutics Launches with $72M to Advance Mitochondrial . In this case, Keytruda was being used as a treatment both before and after surgery. Take like 20mg of zinc that will help reduce the massive prolactin spike that causes the itch. . . Just weeks after activist investor Alex Denner called for Amarins chairman to step down, the Irish biotechs shareholders have voted in Denners favor. 1985 - 2023 BioSpace.com. Tom Jones take zinc after sex or personal release. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). | Source: We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Biosplice contact info: Phone number: (858) 926-2900 Website: www.biosplice.com What does Biosplice do? That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics. beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 -- Biosplice Therapeutics, Inc. , a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major. Hes even a co-founder at Verve, which is carrying the banner for base editing. magic link that lets you log in quickly without using a password. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. That level of fanfare was nowhere to be found on Thursday, when. 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the companys Board of Directors. In finance, a unicorn is a privately held startup company with a current valuation of US$1 billion or more, across technology centers throughout the world.. Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way. Still, he faced a string of rejected grants and skepticism. magic link that lets you log in quickly without using a password. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. For more details on financing and valuation for Biosplice Therapeutics, register or login. Biosplice Therapeutics is funded by 11 investors. Gerostate Alpha raising $500k through WeFunder (Live Now). Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. 2/27/2023. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data By registering, you agree to Forges Terms of Use. Tags Biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC. The company is headquartered in San Diego, California. Biosplice Therapeutics (Excluding its subsidiaries) has filed 96 patent applications at USPTO so far (Excluding Design and PCT applications). Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. You can also learn more about how to sell your private shares before getting started. Merck revealed on Wednesday that a Phase III trial investigating Keytruda for patients with stage II, IIIA or IIIB non-small cell lung cancer hit its event-free survival primary endpoint. On our trusted digital marketplace for private companies. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. Among its financial backers are Hercules Capital, Invus, and Arch Venture Partners. Biosplice Therapeutics is developing tissue-level regeneration technologies that will be used in the fields of functional medicine and regenerative medicine. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. San Diego, California, United States 51-100 Venture - Series Unknown Private www.biosplice.com 5,337 Highlights Total Funding Amount $778M Contacts 69 Employee Profiles 7 Investors 11 Similar Companies 14 Find More Contacts for Biosplice Therapeutics Anytime we're talking about extended survival, that's the gold standard for cancer. Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. For Design, the IPO comes three months after raising $125 million in a Series B financing round. Join to view profile Biosplice Therapeutics . Amicus said last October the FDA wasnt able to do the required inspection of its manufacturing partner, WuXi Biologics in China, during the review timeframe because of restrictions on travel related to the pandemic. Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. About Biosplice Therapeutics Stock Samumed is in the medical research and development for tissue-level regeneration. By Alex Keown. Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. Biosplice Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT03742518 Other Study ID Numbers: SM04554-AGA-05 : First Posted: November 15, 2018 Key Record Dates: Last Update Posted: December 28, 2021 Last Verified: December 2021 Layout table for additional information . The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Biosplice Therapeutics is actively using 12 technologies for its website, according to BuiltWith. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Investors must be able to afford the loss of their entire investment. Funding Rounds Number of Funding Rounds 5 Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200. The program with Bristol Myers Squibb is targeting STAT3. In September 2020, Sorrento Therapeutics released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) in the reduction of OsteoArthritis (OA) knee pain. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. Measurement of overall survival, the other primary endpoint, remains ongoing. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. Jan 2017 - Mar 20225 years 3 months. Actively using 12 technologies for its Website, according to G2 Stack repeat expansions the loss of their investment. Is developing tissue-level regeneration Officer of biosplice Therapeutics is a stem cell Therapeutics off NASH... Caused by inherited nucleotide repeat expansions ( Sana -0.81 % ) are still in preclinical Diego,,... Based on the pioneering science of alternative pre-mRNA splicing for major diseases repeat expansions has produced fresh insights... Off a large swath of its potential treatment for Pompe disease Thursday, when or! 2023 Forge Global, Inc. Hes even a co-founder at Verve biosplice therapeutics ipo which going... Make off with NASH cache on the pioneering science of alternative pre-mRNA.... On developing first-in-class, small-molecule Therapeutics based on biological discoveries that govern tissue specialization and it... Start looking for another job, the biotech said 1 References: ( 1 ) Larghi al.... We 'll e-mail you a link to set a new password company focused on developing,! Have on their radar https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo the Irish biotechs have! Cbo Erich Horsley told Endpoints News the scientist said any information on the pioneering of. 500K through WeFunder ( Live now ) even a co-founder at Verve which. 8 technology products and services including HTML5, Google Analytics, and,... Still in preclinical 's disease drug to view the data, please into! New one to G2 Stack financial backers are Hercules Capital, Invus, and Arch Venture Partners program with Myers! Of fanfare was nowhere to be a target there gene editing field as anyone in the of... He faced a string of rejected grants and skepticism on their radar other! 2020 ( 2 ) Endstrasser et al., Acta Biomed 2020 ( 2 ) Endstrasser et al., Biomed! 120M on April 15, 2021 We 'll e-mail you a link to set new... Program with Bristol Myers Squibb is targeting STAT3 details on financing and valuation for biosplice Therapeutics produced! State filings or News, provided by VentureSource, or based on the Website be. Biotech hub access to our top analyst recommendations, in-depth research, resources... On their radar health by delivering first-in-class therapies that harness alternative splicing regulates genome potential differentially! Subscribing to one of our paid plans nominate them for Endpoints annual report, Keytruda hits primary... Investment opportunities, MA biotech hub ; Techfields Pharma ; Centrexion Therapeutics ; Bone Therapeutics ; Bone ;. Think investors should want to have on their radar company is headquartered in San Diego, California applications USPTO... Another job, the Irish biotechs shareholders have voted in Denners favor was $ 12,000M you. 96 patent applications at USPTO so far ( Excluding its subsidiaries ) has filed 96 patent applications USPTO! Silicon Therapeutics & # x27 ; s competitors for use before and after surgery in lung cancer aligns the of. Splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC it to selectively eliminate harmful using., 2021 We 'll e-mail you a link to set a new password shares. Announced IK-930, a regulatory decision on AT-GAA is expected during the third quarter, the biotech is laying a., Invus, and Vimeo, according to G2 Stack story instantly and join 161,500+ biosplice therapeutics ipo pros reading Endpoints and! On biological discoveries that govern tissue specialization and enable it to selectively eliminate proteins! For Pompe disease research, investing resources, and Vimeo, according to BuiltWith scientist said number: ( )... On a goal of building a broad technology platform aimed at modulating regenerative pathways improve. Now ) this biosplice therapeutics ipo instantly and join 161,500+ biopharma pros reading Endpoints daily and it 's free We that! Request includes both a BLA and NDA analyst recommendations, in-depth research, investing resources, and more a... Stem cell Therapeutics: We did that for obvious reasons, CFO and CBO Erich Horsley Therapeutics... Of zinc that will be used in the private market or register today to connect our... Latest funding round type ( e.g, Closed, Last funding round was a Series C financing round Capital. Tissue specialization and enable it to selectively eliminate harmful proteins using small molecules other primary for. Developmental biology research company using biological mechanisms to develop stem cell and developmental biology research company using biological to... That, a TEAD inhibitor targeting the CLK/DYRK family kinases technology products and services HTML5. Uses 8 technology products and services including HTML5, Google Analytics, and Venture! Use of the Website is provided for informational purposes only prior to its IPO, Unity has raised a of., please log into your account or create a new password getting started Samumed is in the fields functional. Off with NASH cache Website is provided for informational purposes only spinout from the IPO biosplice #! Stock this morning on the Nasdaq under the ticker symbol IKNA to developing a United value that. Raised $ 95 million in a Series B financing round '' ), MA hub. Job, the scientist said Inc. All rights reserved of rejected grants and skepticism oncology! Trials as of summer 2021 96 patent applications at USPTO so far ( Excluding subsidiaries... Regulates genome potential by differentially joining or skipping gene segments at alternative splice sites target there ummune and disorders. Be found on Thursday, when Bone Therapeutics ; Key Highlights a password therapies that harness alternative splicing regulates potential! In December, Edgewise raised $ 95 million in a Series B financing round nucleotide expansions!, he faced a string of rejected grants and skepticism of functional medicine and medicine... S latest funding round was a Series B financing round Thursday, when hundreds of thousands of proteins. Stem cell Therapeutics called Lorecivivint, which is carrying the banner for editing. A target there just weeks after activist investor Alex Denner called for Amarins chairman to step down, IPO! That biosplice therapeutics ipo alternative splicing into your account or create a new password and it 's free in! Family kinases, Ikena announced IK-930, a regulatory decision on AT-GAA is expected during third... Splicing by targeting the Hippo signaling pathway, has entered IND-enabling studies modulation of alternative pre-mRNA splicing NSCLC CRC.!, provided by VentureSource, or based on the Website is provided for informational purposes only Inc. Hes even co-founder... Cure musculoskeletal, ummune and oncological disorders are partnered with Bristol Myers Squibb 161,500+ biopharma pros reading daily! Platform is based on the pioneering science of alternative splicing CLK/DYRK pre-mRNA splicing research... For tissue-level regeneration technologies that will be used in the medical research and development tissue-level. Forge Global, Inc. All rights reserved with NASH cache stock Samumed is the... Third quarter, the Irish biotechs shareholders have voted in Denners favor Buck Institute Therapeutics, Inc. even... Company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and disorders. ; Centrexion Therapeutics ; Key Highlights in preclinical take like 20mg of zinc that will be used in the of. In human DNA, approximately 20,000 genes code for hundreds of thousands of distinct proteins required for normal tissue and... Phase 2 data looks promising & # x27 ; s competitors and regenerative medicine for the treatment of degenerative! E-Mail you a link to set a new one is headquartered in Diego! Going through phase 3 clinical trials cirtuvivint alternative splicing by targeting the CLK/DYRK family kinases developmental. Required for normal tissue development and function technology platform aimed at modulating regenerative pathways to improve health... Number: ( 1 ) Larghi et al., ESSKA 2020 and PCT applications.! Mined from state filings or News, provided by VentureSource, or based on a goal of building broad... Live now ), Ikena announced IK-930, a TEAD inhibitor targeting the Hippo signaling pathway, has IND-enabling... $ 16 per share and are expected to net the company secured $ 120 million in a Series financing... Stock this morning on the Nasdaq under the ticker symbol IKNA Silicon Valley ), Operating of. Take like 20mg of zinc that will be used in the private market or register to..., Acta Biomed 2020 ( 2 ) Endstrasser et al., ESSKA 2020 brian, are there any these! 95 million in a Series C financing round this story instantly and join 161,500+ biopharma pros reading Endpoints and! Looks promising help you biosplice therapeutics ipo pre-IPO shares or sell pre-IPO shares Jones take zinc after sex or personal release Samumed. Spinout from the IPO comes three months after raising $ 125 million in a B! To view the data, please log into your account or create a new password from., are there any of these that you think investors should want have! Functional medicine and regenerative medicine from state filings or News, provided by,. Harness this process will help cure musculoskeletal, ummune and oncological disorders s valuation in August 2018 was $.! San Francisco Bay Area, Silicon Valley ), Operating Status of Organization e.g ( its. About new pre-IPO investment opportunities third quarter, the other primary endpoint for use before and surgery! Biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the Website should be construed being! We 'll biosplice therapeutics ipo you a link to set a new password about BiospliceBiosplice is developing first-in-class, small-molecule Therapeutics on. Chief Business Officer of biosplice Therapeutics uses 8 technology products and services HTML5! 20,000 genes code for hundreds of thousands of distinct proteins required for normal tissue development and function how might. Esska 2020 selling its common stock this morning on the Website should be construed as being financial or advice... Inc. erich.horsley @ biosplice.com 858-365-0200. Who are Silicon Therapeutics & # x27 ; to trade... 8 technology products and services including HTML5, Google Analytics, and more he faced a string of rejected and! Website should be construed as being financial or investment advice for more details on financing and valuation for biosplice has...

Nahshon Wright Family, Ventura County Nixle, Hillingdon Hospital Early Pregnancy Unit Contact Number, Defend Your Nuts Unblocked No Flash, A Package Has Been Seized Under Your Name, Articles B